Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 95.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.93M |
| Shares Out | 14.82M |
| EPS (ttm) | -3.33 |
| PE Ratio | n/a |
| Forward PE | 4.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,312 |
| Open | 6.77 |
| Previous Close | 6.90 |
| Day's Range | 6.56 - 6.85 |
| 52-Week Range | 5.91 - 27.32 |
| Beta | 2.00 |
| Analysts | Strong Buy |
| Price Target | 30.80 (+353.6%) |
| Est. Earnings Date | Nov 15, 2021 |
About ELDN
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the trea...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price forecast is 30.80, which is an increase of 353.61% from the latest price.
News
Eledon Pharmaceuticals to Present at Two Investor Conferences in September
IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons...
A Duo of Net Current Asset Value Stock Picks to Consider
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reasses...
Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results
Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022
Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET
Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transpl...
Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...
Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...
Eledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
IRVINE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons l...
Eledon Pharmaceuticals Reports First Quarter 2021 Operating and Financial Results
Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS)
Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress
IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons l...
Eledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET
Eledon Pharma Stock Jumps Despite FDA Asking For Additional Preclinical Study In Non-Primate Animal Models
As part of ongoing discussions with the FDA regarding Eledon Pharmaceuticals Inc's (NASDAQ: ELDN) AT-1501 renal transplant program, the agency has requested AT-1501 specific renal transplant data in non...
Eledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation
IRVINE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons...
Moving Average Crossover Alert: Eledon Pharma (ELDN)
Eledon Pharmaceuticals (ELDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Eledon Pharmaceuticals Continues to Bolster Leadership Team with Addition of Two More Key Executives
David Hovland, Ph.D., to serve as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer David Hovland, Ph.D., to serve as Chief Regulatory ...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Operating and Financial Results
Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS)
Eledon Pharmaceuticals to Release Fourth Quarter and Full-Year Financial Results on Tuesday, March 30
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET
Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook
Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021
Novus Therapeutics Appoints June Lee, M.D., to Board of Directors
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company's Board of Directors.
Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript
Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript
Novus Therapeutics Reports Third Quarter 2020 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients underg...
Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients underg...
Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyo...
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
Moving Average Crossover Alert: Novus Therapeutics
Novus Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split